Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28598
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcKay, Michael J-
dc.contributor.authorTaubman, Kim L-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorScott, Andrew M-
dc.date2022-01-14-
dc.date.accessioned2022-01-18T04:46:14Z-
dc.date.available2022-01-18T04:46:14Z-
dc.date.issued2022-02-
dc.identifier.citationAnnals of Nuclear Medicine 2022; 36(2): 162-171en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28598-
dc.description.abstractAccurate target delineation is an absolute requirement for modern radiotherapy planning. Historically, structural imaging modalities have been used for this purpose, but there is a considerable role for functional imaging with PET/CT to contribute in this area. PET/CT's role in radiotherapy planning is well established and its use is indispensable in the clinical management of the lymphomas, particularly Hodgkin Lymphoma. A crucial use of PET/CT is as a baseline scan for delineation of the initial lymphomatous involvement, since this will determine the contouring of the gross-, clinical- and planning-target volumes (GTV, CTV, PTV). This article reviews the principles of contemporary radiotherapy, examines the evidence for the contribution of PET/CT to radiotherapy planning in lymphoma and the practicalities and challenges of applying this powerful technology to this situation.en
dc.language.isoeng-
dc.subjectLymphomaen
dc.subjectMetabolic imagingen
dc.subjectPETen
dc.subjectRadiotherapy planningen
dc.titleRadiotherapy planning of lymphomas: role of metabolic imaging with PET/CT.en
dc.typeJournal Articleen
dc.identifier.journaltitleAnnals of Nuclear Medicineen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, VIC, Australiaen
dc.identifier.affiliationFaculty of Medicine, University of Melbourne, Melbourne, VIC, 3052, Australiaen
dc.identifier.affiliationDepartment of Medical Imaging, St Vincents Hospital, Fitzroy, VIC, 3065, Australiaen
dc.identifier.affiliationRural Clinical School, Northwest Regional Hospital, University of Tasmania, Burnie, TAS, 7320, Australiaen
dc.identifier.affiliationNorthern Cancer Service, North West Cancer Centre, Burnie, TAS, 7320, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35028879/en
dc.identifier.doi10.1007/s12149-021-01703-7en
dc.type.contentTexten
dc.identifier.orcid0000-0001-8641-456Xen
dc.identifier.orcid0000-0002-6656-295Xen
dc.identifier.pubmedid35028879-
local.name.researcherLee, Sze Ting
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

52
checked on Nov 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.